Cell and Gene Therapy Manufacturing Market to Skyrocket to $146B by 2032

Why It Matters

The explosive market expansion signals massive investment opportunities for manufacturers and service providers, while faster regulatory pathways could accelerate patient access to life‑saving therapies.

Key Takeaways

• Market grows from $19.3B to $146.2B by 2032.
• CAGR projected at 28.8% through 2032.
• North America holds 45% share, Europe 30%.
• Regulatory approvals expected to boost manufacturing capacity.
• Automation and scalable processes drive industry expansion.

Pulse Analysis

The cell and gene therapy sector is entering a period of unprecedented scale, driven by the convergence of personalized medicine and breakthroughs in viral‑vector and CRISPR technologies. As biotech firms move beyond early‑stage trials, the need for reliable, high‑throughput manufacturing becomes a strategic differentiator. Investors are watching the market’s projected 28.8% CAGR, recognizing that capacity constraints could become a bottleneck for next‑generation treatments, from CAR‑T cells to gene‑editing therapies.

Geographically, North America’s 45% share reflects its mature regulatory framework and concentration of biotech hubs, while Europe’s 30% underscores strong public‑private partnerships and reimbursement models. Asia‑Pacific, though currently smaller, is attracting significant capital as governments launch incentives for advanced therapy manufacturing. This regional shift is prompting a wave of new facilities, joint ventures, and technology transfer agreements, reshaping the global supply chain and creating cross‑border opportunities for equipment vendors and contract manufacturing organizations.

Regulatory dynamics are equally pivotal. The anticipated departure of CBER Director Vinay Prasad may ease some of the contentious review processes that have slowed approvals for rare‑disease gene therapies. Coupled with an expanding late‑phase pipeline—18 candidates under FDA review—manufacturers are preparing for a surge in demand. Automation, single‑use bioreactors, and digital twins are being adopted to meet scale while maintaining product consistency, positioning the industry for sustainable growth through 2032 and beyond.